The 14.92% discount and ~4.5-5.4% dilution create near-term selling pressure. Monitor for over-allotment exercise announcement and any subsequent insider selling after the 90-day lock-up expires. The cash runway extension into 2029 reduces near-term financing risk but does not change the fundamental thesis around NBTXR3 approval.
Price Chart
Executive Summary
Nanobiotix priced a global follow-on offering of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants at $38.98 per ADS / €33.60 per share, a 14.92% discount to the VWAP. Gross proceeds are expected to be ~$98.6M (~€85M), with net proceeds extending the cash runway into 2029. The dilutive offering (4.5-5.4% of shares outstanding) is bearish for existing holders, though the cash infusion funds pipeline advancement.
Key Financial Metrics
Key Facts
- Pricing at $38.98 per ADS / €33.60 per share, a 14.92% discount to the 3-day VWAP on Euronext
- Aggregate gross proceeds of ~$98.6M (~€85M) from 2,184,662 ordinary shares and 345,099 pre-funded warrants
- Underwriters have a 30-day option to purchase up to 15% additional ADSs (over-allotment)
- Existing shareholders Qatar Holding LLC and Invus participated in the offering
- Net proceeds to be used: <10% for JNJ-1900 (NBTXR3), 50-60% for Nanoprimer and other platforms, 30-40% for general corporate purposes
- Cash runway extended into 2029 based on current burn rate
- Insiders subject to 90-day lock-up; company also locked up for 90 days
- Offering expected to close May 26, 2026
Financial Impact
~$98.6M gross proceeds raised at a 14.92% discount to VWAP; dilution of ~4.5% (excluding over-allotment and PFW) to ~5.4% (including full exercise of over-allotment and PFW)
Risk Factors
- Dilution of ~4.5-5.4% for non-participating shareholders
- Potential downward price pressure from the discounted offering and possible over-allotment
- Execution risk on pipeline advancement with the raised capital
- Lock-up expiry in ~90 days could lead to insider selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299514 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $31.53 (+22.07%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.53 (+5.34%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.53 (−10.53%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.53 (−11.75%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.53 (−18.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers